Page 5,330«..1020..5,3295,3305,3315,332..5,3405,350..»

CVS Pharmacy wants to open store in Hastings

Posted: Published on May 11th, 2013

CVS Pharmacy has its sights set on building a store in Hastings, along the city's main drag. A concept plan discussed at the city's planning committee last month shows the pharmacy building and a parking lot occupying an entire city block along the east side of Vermillion Street, between 14th and 15th streets. Several homes and businesses, including Hastings Gift Garden & Floral and a Great Clips, currently occupy the site. CVS Pharmacy has met with the land owners to talk about purchasing their properties, City Administrator Melanie Mesko Lee said, adding she was unsure how far along the process has evolved. City officials and CVS Pharmacy have scheduled a neighborhood meeting to talk about the proposal. It will be at 7 p.m. Tuesday, May 14, at City Hall. Input from the meeting will help CVS Pharmacy in developing final plans for city review and consideration, Mesko Lee said. Nick Ferraro can be reached at 651-228-2173. Follow him at twitter.com/NFerraroPiPress. View post: CVS Pharmacy wants to open store in Hastings … Continue reading

Posted in Pharmacy | Comments Off on CVS Pharmacy wants to open store in Hastings

Advanced Cell Technology Announces 2013 First Quarter Results

Posted: Published on May 10th, 2013

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT or the Company; OTCBB: ACTC) a leader in the field of regenerative medicine, announced today its first quarter financial results for the period ended March 31, 2013. The Company reported a loss from operations of $(5.8) million compared to a loss from operations of $(5.4) million in the 2012 first quarter, primarily as a result of higher clinical trial expenses. ACT reported a net loss of $(6.4) million or $(0.00) per share, compared to a loss in the same period in 2012 of $(5.7) million or $(0.00) per share. Net cash used in operations for the 2013 first quarter was $8.3 million, compared to net cash used in operations of $4.8 million during the same period in 2012. The Company ended the 2013 first quarter with cash and cash equivalents of $4.1 million, compared to $7.2 million as of December 31, 2012, primarily due to higher operating expenses. Cash utilization increased significantly as a result of $2.3 million used to settle litigation related to previously issued debentures. The Company expects cash utilization to return to previous levels in the subsequent quarter. Highlights from the first quarter of 2013 included: I am pleased … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Advanced Cell Technology Announces 2013 First Quarter Results

StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business Update

Posted: Published on May 10th, 2013

NEWARK, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the first quarter ended March 31, 2013 and provided a business update. "In the first quarter, we reported the most recent data from our spinal cord injury trial, which showed that the multi-segmental gains in sensory function observed at the six-month time point in two of three patients had persisted through the twelve-month assessment, and that one of the two had converted from a complete injury to an incomplete injury classification," said Martin McGlynn, President and CEO of StemCells, Inc. "This exciting development follows the publication, last fall, of the data from our Phase I PMD trial showing evidence of new myelin formation on the nerve axons of all four patients in the trial and gains in neurological function in three of the four patients. Our encouraging data to date tells us that we are on the right track, and we are now focused on accelerating enrolment in our ongoing trials. We have taken concrete steps to this end in our spinal … Continue reading

Posted in Stem Cell Human Trials | Comments Off on StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business Update

BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments

Posted: Published on May 10th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2013 and highlighted recent corporate accomplishments. First Quarter and Recent Corporate Accomplishments Financial Results Net Loss Net loss attributable to BioTime, Inc. for the first quarter of 2013 was $7.7 million or $0.15 per share, compared to a net loss of $5.0 million or $0.10 per share for the same period of 2012. Contributing to the increased expenses year-over-year was approximately $1 million in organization, legal, and start up costs associated with Asterias. The other subsidiaries combined for approximately $4 million of other operating losses, with the balance of the operating loss of approximately $3 million residing in BioTime. Historically BioTime's subsidiaries have raised capital, received grants, and generated revenues independently of BioTime to help fund their operations; we expect the subsidiaries to continue to pursue such financing strategies in the future. Revenue Total net revenue, including license fees (which also include online database subscription and advertising revenues), royalties from sales of Hextend, research product sales, and grant income, on a consolidated basis, was $0.4 million in … Continue reading

Posted in Stem Cell Human Trials | Comments Off on BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments

Bid for MS breakthrough

Posted: Published on May 10th, 2013

University of Adelaide researchers are working on a stem cell project they hope will lead to a new treatment for multiple sclerosis (MS). They have started a three-year project using adult stem cells to directly target the damaged site in the central nervous system (CNS). Multiple sclerosis is an autoimmune inflammatory disease of the brain and spinal cord. To control the disease, effective treatments need to control the immune response and repair damage to nerve-protection sheaths. 'We've already shown adult stem cells have great potential to control the immune response and promote repair of the central nervous system,' says Professor Shaun McColl in a statement timed to coincide with Kiss Goodbye to MS month. He said the trick was to get the stem cells to the right location. 'We aim to show we can modify stem cells to more effectively reach the central nervous system, and that we can use these cells to inhibit inflammation. 'If it works, there is great potential for a new therapy for this debilitating disease.' Read more here: Bid for MS breakthrough … Continue reading

Comments Off on Bid for MS breakthrough

Multiple sclerosis hope 'lie in stem cells'

Posted: Published on May 10th, 2013

Professor Shaun McColl says new treatment for multiple sclerosis lies within modified adult stem cells. Picture: Dean Martin Source: adelaidenow A POTENTIAL new treatment for multiple sclerosis lies within modified adult stem cells, University of Adelaide researchers say. The researchers hope using stem cells from fat tissue - to send cells with anti-inflammatory properties directly to the damaged site in the central nervous system - will be able to treat the autoimmune disease. Director of the Centre for Molecular Pathology, Professor Shaun McColl, said treatments for MS needed to control the immune response and repair the damage caused to the fatty myelin sheaths that protect the nerves. "We've already shown that adult stem cells have great potential to both control the immune response and promote repair of the central nervous system. It also prevents further damage," Prof McColl said. "But the trick is getting the stem cells to the right location where they can perform this function." MS is a progressive disease in which the body attacks the central nervous system, causing nerve inflammation and scarring. It results in the impairment of motor, sensory and cognitive function. When stem cells are injected into theblood system, very few cross the blood/brain … Continue reading

Comments Off on Multiple sclerosis hope 'lie in stem cells'

Army stem cell project questioned

Posted: Published on May 10th, 2013

BANGKOK - A former director of Veterans General Hospital is campaigning against the hospital's decision to pursue stem cell research. Namchai Kultaraporn outlined his concerns in a document he distributed on Friday at a ceremony held at the hospital in Bangkok to announce cooperationinvolving local and foreign researchers. Stem cell treatment, he wrote, still requires a lot more research before it can be accepted in mainstream medicine. There are many medical safety, legal and ethical issues, he added. Dr Namchai also questioned the transparency of the decision to begin research. He said the current director, Gen Chaiwat Sathondi, who took office on April 2, entered agreements with private and public agencies without consulting the hospital's management team. Nobody knew the details of the cooperation or the organisations he had contacted, said Dr Namchai. "Despite what was presented [at the ceremony], there are still no reasons for the hospital to have a stem cell project," Dr Namchai said. The hospital has received budget approval to expand to 500 beds from 300 and that should be the priority, rather than renovation of building for other purposes, he added. Defence Minister Sukumpol Suwanatat attended the event and said that stem cell treatment was … Continue reading

Comments Off on Army stem cell project questioned

Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments

Posted: Published on May 10th, 2013

CAMBRIDGE, MA--(Marketwired - May 9, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three months ended March 31, 2013, and provided an update of recent corporate developments. "We are encouraged by our initial interactions with the U.S. Food and Drug Administration regarding a potential accelerated approval regulatory path for eteplirsen for the treatment of Duchenne muscular dystrophy, and we are finalizing a response to the FDA's request for more data to help us determine the feasibility of this pathway," said Chris Garabedian, president and chief executive officer of Sarepta Therapeutics. "In parallel, we continue to advance the clinical, regulatory, and manufacturing activities for eteplirsen and our additional DMD product candidates to build a successful franchise in this important disease area." Financial Results For the first quarter of 2013, Sarepta reported a Non-GAAP operating loss of $13.3 million, compared to a Non-GAAP operating loss of $6.1 million for the first quarter of 2012. The incremental loss is primarily the result of a $6.7 million decrease in government contract revenues as well as a $0.5 million increase in operating expenses. On a GAAP basis, the operating loss for the first quarter … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments

Epilepsy Treatment for FREE with EPILEPSY FOUNDATION – Video

Posted: Published on May 10th, 2013

Epilepsy Treatment for FREE with EPILEPSY FOUNDATION Patient speaking about his treatment at Free Epilepsy Camps. His son has recovered well and now he is not getting any seizure and under control. By: epilepsyfound … Continue reading

Comments Off on Epilepsy Treatment for FREE with EPILEPSY FOUNDATION – Video

Epilepsy Medical Assessment – Video

Posted: Published on May 10th, 2013

Epilepsy Medical Assessment San Joaquin Delta College 2013-Group 4. By: Zaina Ahmed … Continue reading

Comments Off on Epilepsy Medical Assessment – Video

Page 5,330«..1020..5,3295,3305,3315,332..5,3405,350..»